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ST2 is a member of the IL-1 receptor family and IL-33 was recently identified as its natural
ligand. The IL-33/ST2 pathway regulates Th1/Th2 immune responses in autoimmune and
inflammatory conditions, but the role of ST2 signaling in tumor growth and metastasis has
not been investigated. We aimed to investigate whether ST2 gene deletion affects tumor
appearance, growth, andmetastasis, and antitumor immunity in an experimental metastatic
breast cancer model. Deletion of ST2 in BALB/c mice bearing mammary carcinoma atten-
uated tumor growth and metastasis, which was accompanied by increased serum levels of
IL-17, IFN-c, and TNF-a and decreased IL-4. Tumor-bearing ST2/ mice had significantly
higher percentages of activated CD27highCD11bhigh NK cells, CD691 and KLRG NK cells and
higher cytotoxic activity of splenocytes, NK cells, and CD81 T cells in vitro. A significantly
higher number of NK cells expressing IFN-c were found in ST2/ mice compared with WT
recipients. In vivo depletion of CD81 or NK cells revealed a key role for NK cells in enhanced
antitumor immunity in ST2/ mice. We report for the first time that suppressed breast
cancer progression and metastasis in mice lacking ST2 corresponds mainly with enhanced
cytotoxic activity of NK cells, and increased systemic Th1/Th17 cytokines.
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Introduction
The ST2 gene, also called T1, DER-4 and Fit-1, is a member of the
interleukin-1 receptor (IL-1R) family that was originally identi-
fied in oncogene- or serum-stimulated fibroblasts [1, 2].
Differential mRNA processing within the ST2 gene generates
three isoforms: a soluble form (sST2), a membrane-anchored
form (ST2L), and a variant ST2 (ST2V) which is localized on the
plasma membrane and predominantly expressed in the stomach,
small intestine, and colon [3–5]. Soluble ST2 is found in
embryonic tissues, and is secreted by macrophages, Th2 cells,
and fibroblasts [1–5]. ST2L is an orphan receptor expressed on a
variety of cell types including mast cells, basophils, eosinophils,
dendritic cells, macrophages, Th2 cells, and NK and iNKT cells
[3–15]. A member of the IL-1 family, IL-33, previously known as
a nuclear factor in high endothelial venules, has been recently
described as a natural ligand for ST2L [16]. IL-33 is expressed in
multiple tissues and has been shown to induce the secretion of
both proinflammatory and anti-inflammatory cytokines from
mast cells, eosinophils, and Th2 lymphocytes [3, 17]. IL-33 is a
potent activator of Th2 cells and has a dual role in disease [3, 16].
IL-33/ST2 signaling has a protective role against parasites, in
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atherosclerosis, and obesity, but it can enhance Th2 and mast
cell-mediated diseases such as asthma and anaphylaxis. The role
of IL-33/ST2 signaling in antitumor immunity is unknown.
Breast cancer is one of the leading causes of cancer deaths
among women worldwide [18]. The initiation of breast cancer
might be caused by a combination of oncogenic mutations that
promote genetic instability and accelerated cellular proliferation
[19]. The major cause of breast cancer deaths is the development
of distant organ metastasis in lungs, bones, liver, and brain [20].
In breast cancer, antitumor immune responses are neither potent
nor effective [21].
Th1 and Th2 cells have important immunoregulatory roles in
cancer development [22]. Data from numerous reports suggest
that Th1-type antitumor immunity provides a greater therapeutic
index and promotes durable antitumor CTL responses that are
associated with tumor regression. Although Th2-type cytokines
downregulate antitumor immunity, they can promote the recruit-
ment of tumoricidal eosinophils and macrophages into the tumor
microenvironment [23–26]. ST2L is a stable and selective marker
of both murine and human Th2 cells, but not Th1 cells
[3, 5, 8, 15, 27–29] and ST2L signaling enhances Th2 effector
functions [3, 5, 8, 28–30]. Abs against ST2, ST2-Fc fusion proteins
or use of ST2-deficient mice in various pathological conditions
revealed that lack of IL-33/ST2 signaling favors the expansion of
Th1/Th17 cells and inhibits Th2 cell-mediated immune responses
[3, 5, 28, 31]. Activity of natural killer (NK) cells is the major
mechanism of innate immunity against tumors [32]. NK cells lyse
tumor cells without prior sensitization and represent the first line
of defense against tumors and cancer metastasis [32]. Recently,
the ST2L molecule has been shown to be constitutively expressed
on murine and human NK and iNKT cells [9, 10].
In this study, using the 4T1 metastatic breast cancer model in
ST2-deficient BALB/c mice, we aimed to investigate whether the
lack of ST2 signaling affects tumor growth and metastasis and
mechanisms of antitumor immunity.
Results
ST2-defficient mice show delayed mammary tumor
appearance, slower tumor growth, and progression
The 4T1 metastatic breast cancer model is a syngeneic xenograft
model in which the 4T1 mouse mammary tumor cell line (5104
cells) is introduced orthotopically into the mammary fat pad of
WT or ST2/ BALB/c mice by injection. When introduced
orthotopically, the 4T1 line grows rapidly at the primary site and
forms metastases in lungs, liver, bone, and brain, which makes
this an excellent model for the study of metastatic progression of
breast cancer in humans. As this model is syngeneic in BALB/c
mice, it can be used to study the antitumor immune mechanisms
in tumor growth and metastasis [33].
After the injection of 4T1 tumor cell line, mammary tumor
growth was measured daily and tumor volumes assessed at day
36. As shown in Fig. 1A, tumor appearance was significantly
delayed in ST2/ compared with WT mice. Mean value of time
period in days from inoculation of tumor cells to the appearance
of palpable primary tumor in ST2/ mice was significantly
longer compared with WT mice (mean7SEM: 8.67 days70.21
versus 7.20 days70.37, po0.05). On day 36, the mean value of
primary tumor diameter in WT mice was significantly higher than
in ST2/ mice (13.16mm70.79 versus 10.18mm70.23,
po0.01). Similarly, primary tumor volume was significantly
higher in WT mice (1047.24mm37159.48 versus 517.31mm37
26.66, po0.01). Systemic tumor cell dissemination was deter-
mined by microscopic evaluation of parenchymal tissues. Six out
of seven WT mice (86%) developed numerous lung metastatic
colonies, whereas only 3 out of 12 ST2/ mice (25%) developed
lung metastasis (po0.01) as shown in Fig. 1B. The incidence of
liver metastasis was also significantly lower in ST2/ mice (1/
12; 8%) compared with WT mice (4/7; 57%, po0.05) (Fig. 1B).
Brain metastasis was not found in WT or ST2/ mice at this time
point. In addition to the marked difference in the number of
metastatic colonies in lungs and livers, the significant difference
in the size of metastatic colonies was also observed, being
evidently and significantly smaller in ST2/mice compared with
WT animals (Fig. 1B and C).
Cellular makeup of local lymph nodes and spleens in
ST2/ and WT mice after tumor challenge
Tumor cell inoculation led to an increase in cellularity of local
lymph nodes in both groups of mice at day 13. Absolute numbers of
CD31 cells in the spleens were also increased, but reached statistical
significance only in ST2/ mice (po0.05; Fig. 2). Similarly,
percentages (data not shown) and absolute numbers of CD41 and
CD81 T cells were significantly increased in local lymph nodes and
spleens in ST2/ mice compared with tumor-bearing WT mice
(po0.05; Fig. 2). On the contrary, absolute numbers of CD191 cells
were markedly increased in both local lymph nodes and spleens of
tumor bearing WT mice compared with ST2/ recipients (data not
shown). We found no difference in the absolute numbers of F4/801
macrophages between ST2/ and WT animals, prior to and 13
days after tumor challenge (data not shown).
Increased serum levels of Th1/Th17 cytokines after
tumor inoculation in ST2/ mice
We measured Th1, Th17, and Th2 cytokine levels in the sera of
WT and ST2/ mice prior to and at day 36 after tumor
inoculation. Serum IL-17, IFN-g, and IL-4 levels were not
detectable and serum TNF-a level was low in healthy mice in
both groups, i.e. before tumor inoculation. At day 36, tumor
inoculation led to a significant increase in serum IL-17,
IFN-g, and TNF-a levels in ST2/ mice compared with WT
animals (po0.05). On the contrary, a significant increase in serum
IL-4 levels was observed only in tumor-bearing WT mice (po0.01;
Fig. 3).
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ST2-deficient mice have lower number of NK cells, but
higher number of IFN-c1 NK cells in spleens
In order to dissect out the contribution of NK cells in enhanced
antitumor activity in ST2/ mice, we enumerated
CD3CD19NKp461 cells. Interestingly, number of these cells in
the spleen was lower in tumor naive ST2/ mice in comparison
with WT mice (Fig. 4; po0.05). We also assessed the frequency and
cell number of NKp461 cells producing IFN-g or IL-10 in naı¨ve mice
and following tumor challenge. The total number of IFN-g-
producing NK cells was markedly higher in ST2/ mice prior to
and following tumor challenge (po0.05). IL-10-producing NK cells
were detected only in WT mice after tumor inoculation (po0.05).
Lack of ST2 signaling is associated with higher
antitumor cytotoxicity
ST2 deficiency led to enhanced cytotoxic activity of splenocytes at
the target–effector (T:E) ratios of 1:50 and 1:100 in both healthy
and tumor-bearing mice (Fig. 5A). Interestingly, there were no
differences in cytotoxic activity of splenocytes in healthy and
tumor-bearing ST2/ mice (evaluated by lytic units), but it was
always significantly higher in ST2/ compared with WT mice
(po0.01).
In order to define the effector cells responsible for enhanced
cytotoxic capacity of splenocytes, we isolated CD49b1 NK
cells and tested their antitumor cytotoxicity. The data (Fig. 5)
clearly demonstrated higher cytotoxicity of NK cells derived from
spleens of healthy ST2-deficient mice when compared with WT
mice (po0.01). Interestingly, NK cell activity of the splenic
CD49b1 cells was decreased in both tumor-bearing groups, but
remained significantly higher in ST2/ mice (po0.01).
We next tested cytotoxic activity of CD81 T cells against
tumor cells. As shown in Fig. 5, there was a significant increase in
CD81 T cells mediated cytotoxicity after tumor inoculation
which was higher in ST2/ mice in comparison with WT
mice (po0.05). In addition, activated NK and T cytotoxic cells
(CD107a1) were more frequent in ST2/mice (Fig. 5B). Similar
results were obtained when cytotoxicity and CD107a expression
were evaluated using pooled lymph node cells (data not shown).
Finally, we found that adherent cells derived from spleen were
not responsible for the enhanced cytotoxic capacity of spleno-
cytes derived from ST2/ mice (data not shown).
Figure 1. ST2 deletion attenuates tumor growth and metastasis. (A) WT (n57, black bars) and ST2/ mice (n5 12, white bars) were inoculated with
5 104 4T1 breast tumor cells. Palpable tumors were monitored for 36 days. Black line, WT mice; grey line, ST2/ mice. Tumor diameters were
measured every day. Tumor volumes were determined on day 36 from the inoculation of 4T1 tumor cells. Data are presented as mean1SEM from
two experiments. Statistical significance was tested by Mann–Whitney Rank Sum test or Student’s unpaired t-test, where appropriate (po0.05;
po0.01). (B) Paraffin-embedded lung and liver tissues were stained with hematoxylin and eosin (H&E) and examined by light microscopy for the
number and size of metastatic colonies. H&E-stained sections (4mm) from at least three different levels were examined. Data are presented as mean
1SEM from two experiments. Statistical significance was tested by Mann–Whitney Rank Sum test or Student’s unpaired t-test, where appropriate
(po0.05). (C) Light-microscopic pictures (magnification, 10 ) through pulmonary and liver tissue sections showing metastatic colonies (arrows).
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ST2-deficient mice have a higher percentage of active,
cytotoxic NK cells with faster turnover
As NK cell cytotoxicity appears to be an important contributor to
antitumor activity in experimental mammary carcinoma, we
analyzed NK cells for their constitutive phenotype. The data
shown in Fig. 6A demonstrate that spleens of ST2-deficient mice
had higher percentages of activated, CD27highCD11bhigh NK cells
(po0.05) known to be cytokine producing, cytotoxic, and
tumoricidal, as well as immature CD27high CD11blow NK cells
(po0.01) and a lower percentage of mature CD27low CD11bhigh
NK cells (po0.01). The same trend in NK cell maturation
dynamics was observed in local lymph nodes. We also found
higher percentages of CD691 and killer cell lectin-like receptor
G1 (KLRG1) NK cells in both spleen and local lymph nodes of
ST2/ mice, compared with WT mice (po0.05; Fig. 6B); the
findings support an activated state of NK cells.
Depletion of NK cells but not CD81 cells accelerates
tumor growth in ST2/ mice
To evaluate the relative contribution of CD81 cells and NK cells in
the enhanced antitumor immunity in ST2/ mice in vivo, we
depleted either one or the other cell population, following tumor
challenge in ST2/ and WT animals. CD81 lymphocytes were
depleted by administration of an anti-CD8 mAb on days 1 and
15 of the experiment. Mice were inoculated with 5 104 4T1
tumor cells and followed for tumor growth (Fig. 7A). Such
treatment resulted in a significant reduction of CD81 cells in
spleens as shown in Fig. 7A. After in vivo depletion of CD81 cells
tumor growth remained slower in ST2/ mice compared with
WT animals, similar to that which was observed in intact animals
(Fig. 7A). We next depleted NK cells by in vivo administration of
an antiasialo-GM1 Ab as shown in Fig. 7B. When NK cells were
depleted in vivo, tumor growth was accelerated in both groups of
mice, and the difference of the tumor growth in ST2/
compared with WT mice could no longer be observed (Fig. 7B).
The obtained results indicate a key role for NK cells in the
enhanced antitumor immunity in ST2/ mice.
Figure 2. Flow cytometric analysis of the local lymph node and spleen
T cells. Total cell number of local lymph nodes and spleens were
determined in healthy and tumor-bearing WT and ST2/ mice on day
13 after inoculation of 4T1 tumor cells. Percentages and absolute
numbers of CD31, CD41, and CD81 cells were determined by staining
local lymph node or spleen cell suspensions with fluorochrome-
labeled Abs and analyzed by a FACSAria flow cytometer (BD
Biosciences). Mononuclear cells were gated on by size and granularity
on FSC/SSC. Data are presented as mean1SEM of two separate
experiments, each carried out with four mice per group. Statistical
significance was tested by Student’s t-test (po0.05; po0.01).
Figure 3. ST2-deficiency enhances systemic Th1/Th17 cytokine levels in mice with established tumors. Serum levels of IL-17, IFN-g, IL-4, and
TNF-a in healthy and tumor-bearing WT and ST2/ mice were determined by ELISA at day 36 after inoculation of 4T1 tumor cells. Data are
presented as mean1SD from at least five mice per group. Statistical significance was tested by Student’s t-test (po0.05;po0.01).
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Discussion
In the present study, we examined whether the lack of IL-33/ST2
signaling affects antitumor immunity in an experimental murine
model of mammary carcinoma. For the first time, we showed the
delayed appearance of palpable primary tumor in ST2/
recipients as well as slower tumor growth. ST2 deletion also
inhibited the formation and growth of metastasis. By day 36, the
incidence of spontaneous lung and liver metastasis was signifi-
cantly lower in ST2/ mice, compared with WT mice.
Furthermore, the number and size of metastatic nodules were
evidently smaller in ST2/ recipients (Fig. 1).
Antitumor immunity is mediated by the innate and adaptive
immune system [21–24, 32]. The important role of T cells in
antitumor immunity is well established [22–24]. CD41 Th cells
play an important role in the regulation of the CD81 T-cell-
mediated immune surveillance [23–24, 26]. Th cell polarization
influences antitumor activities in a dual manner. Th1 cells
preferentially activate cellular immunity (by producing IFN-g and
IL-2) and Th2 cells suppress cellular immunity eliciting humoral
immunity (by IL-4, IL-5 IL-10, and IL-13 production; [23, 25, 26,
34]). Th1-mediated antitumor immune response is followed by
potent stimulation of T-cell cytotoxic activity [22–24, 35]. On the
contrary, Th2 polarization results in the production of growth
factors and cytokines that support tumor growth and metastasis
[25]. Several studies, using antiST2 mAbs, ST2-Fc fusion proteins
or ST2-deficient mice demonstrated that the deletion of
IL-33/ST2 signaling favors the expansion of Th1/Th17 cells and
have inhibitory effect on Th2-associated immune response in
various inflammatory and autoimmune disorders [3, 5, 28, 31,
36, 37].
In our study, the analysis of serum cytokines revealed higher
expression of IL-17, IFN-g, and TNF-a in ST2/ mice challenged
with 4T1 breast cancer cells (Fig. 3). On the contrary, serum IL-4
level was significantly higher in WT mice. Thus, preferential
activation of Th1 cells may be important for enhanced antitumor
immunity in ST2-deficient mice.
ST2 deletion enhances lymphopoiesis in local lymph node and
spleen after tumor inoculation and increases the total number of
CD41 and CD81 T cells (Fig. 2). Furthermore, we found signifi-
cant increase of CD81 T-cell-mediated cytotoxicity in vitro after
tumor inoculation in ST2/ mice in comparison with WT mice.
This hints at a role of IL-33/ST2 signaling in the Th2 polar-
ization of immune response in the breast cancer model. In line
with our study, Sweet et al. [38] showed that, after LPS chal-
lenge, levels of proinflammatory cytokines were elevated in the
sera from mice treated with anti-ST2 Ab compared with the
control group, probably by blocking of the Th2 response.
Figure 4. Flow cytometric analysis of NK cell surface markers and intracellular IFN-g/IL-10 in spleens of tumor bearing ST2/ and WT mice.
(A) The percentages and absolute numbers of CD3CD19NKp461 cells in spleens of healthy and tumor-bearing WT and ST2/ mice were
determined on day 13 after tumor inoculation by using fluorochrome-labeled Abs and analyzed on a FACS Aria. Mononuclear cells were gated on
by size and granularity on FSC/SSC. Results are presented as mean1SEM from eight mice per group (po0.05). (B) Following surface staining for
NKp46 cell marker, splenic cells were permeabilized and intracellular staining of IFN-g (12 mice per group) and IL-10 (four mice per group) in WT
and ST2/ mice, prior to and on day 13 after tumor inoculation were performed. Data represent mean1SEM from two separate experiments.
Statistical significance was determined by Student’s t-test (po0.05).
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In addition, we examined the cytotoxic capacity of splenocytes
and found that ST2/ splenocytes had enhanced both consti-
tutive and cytotoxic activity after tumor cell inoculation, when
compared with WT mice (Fig. 5). In order to dissect which cell
population is responsible for this higher cytotoxicity, we tested
NK and CD81 T cytotoxic cells activity in vitro and found the
increased cytotoxicity of both cell types in ST2/ mice. The ST2
molecule is expressed on human and murine NK cells and
IL-33/ST2 signaling may have influence on NK cell function
[9, 10]. The number of NK cells was decreased in naı¨ve ST2/
mice, but the total number of IFN-g-expressing NK cells was
markedly higher in ST2/ mice, before and following tumor
challenge (Fig. 4). On the contrary, the number of IL-10-produ-
cing NK cells was higher in WT mice after tumor inoculation.
The role of the IL-33/ST2 axis on NK cells function is not
fully understood. There are reports that IL-33 can directly
stimulate [9] or indirectly amplify [10] responses of iNKT and NK
cells. However, the IL-33-dependent enhancement of IFN-g
production by these cells always required the presence of IL-12.
Our results from this breast tumor model appear to be at variance
with these reports. It appears that the total number of
CD3CD19NKp461 cells in the spleen is higher in WT than in
ST2/ mice prior to tumor inoculation (Fig. 4A) and decreases
after tumor challenge.
Furthermore, our results suggest that at least during
in vivo tumorigenesis ST2 deletion favors the induction of IFN-g-
producing NK cells (Fig. 4B). Additionally, NK cell-mediated
cytotoxicity was higher in ST2/ mice prior to and following
tumor challenge (Fig. 5A). One possible explanation of this
discrepancy may be related to in vivo maturation of dendritic
cells in ST2/ mice and their effect on NK cells [39].
Dendritic cells with a mature phenotype appear to be required
for the functional maturation of NK cells [39]. Mayuzumi
et al. [13] have recently demonstrated that conventional myeloid
DCs from IL-33 supplemented cultures are immature and
resistant to phenotypic and functional maturation. Thus,
it could be assumed that an in vivo lack of ST2 signaling may
facilitate maturation of dendritic cells. In fact, we have
obtained data indicating that percentage and number of CD11c1
CD80highCD86high DCs was significantly higher in the local lymph
nodes of ST2/ tumor-bearing mice compared with WT mice
(data not shown).
We next analyzed NK cells for their constitutive functional
phenotype. In mice, CD27 expression divides NK cells into
CD27high and CD27low subpopulations with distinct responsive-
ness and migratory capacity [40]. CD27high NK cells showed
greater responsiveness to activating ligands expressed on tumor
cells and demonstrated effective cytotoxicity against tumor target
cells [40]. The C-type lectin receptor CD69 represents an early
activating marker and may play a direct role in mediating cyto-
toxicity against tumor target cells [41], whereas KLRG1 is a
C-type lectin inhibitory receptor, expressed on a subset of mature
NK cells that produce low levels of IFN-g and have a slow in vivo
turnover rate and low proliferative responsiveness to IL-15 [42].
ST2/ mice have a significantly higher percentage of
CD27highCD11bhigh NK cells as well as immature CD27high
CD11blow NK cells, but a lower percentage of CD27low CD11bhigh
NK cells. Additionally, ST2/ mice have higher percentages of
CD691 and KLRG NK cells. Thus, our data suggest that ST2/
Figure 5. Cytotoxic activity of total splenocytes, NK cells, and CD81
T cells. (A) The cytotoxic activity of effector cell populations was tested
in a 4-h MTT assay against 4T1 cell targets, at four different T:E ratios at
day 13. The data are presented as mean percentages of specific
cytotoxicity and LU20/10
7 NK cells, which was calculated on the basis of
mean percentages of killing in four different T:E ratios and percentages
of effector cells. Data are means1SEM of two individual experiments,
each carried out with three mice per group. Statistical significance was
tested by Student’s t-test (po0.05; po0.01). (B) Flow cytometric
analysis of CD107a expression on NKp461 and CD81 cells. Data are
means1SEM of two individual experiments, each carried out with
three mice per group. Statistical significance was tested by Student’s
t-test (po0.05).
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mice have a significantly higher percentage of highly active,
cytokine producing, cytotoxic, and tumoricidal NK cells and
immature NK cells (Fig. 6), suggesting that ST2/ mice may
have faster turnover of NK cells and enhanced cytotoxic activity
when compared with WT mice.
Finally, in order to analyze how the data of in vitro-enhanced
cytotoxicity of CD81 and NK cells in ST2/ mice relate to in vivo
tumor growth, we performed experiments of in vivo depletion of
either CD81 or NK cells. In CD8-depleted mice, tumor growth
remained slower in ST2/ mice, whereas in NK-depleted mice
the difference in tumor growth between ST2/ and WT mice
could no longer be observed. This finding indicates that NK cells
play a more important role than CD81 cells in the enhanced
antitumor immunity in ST2/ mice.
Figure 6. Phenotype of NK cells derived from spleen and local lymph nodes of ST2/ and WT mice. (A) The percentages and absolute numbers of
activated CD27highCD11bhigh NK cells, as well as immature CD27high CD11blow NK cells and mature CD27low CD11bhigh NK cells in the spleen and
local lymph nodes of healthy and tumor-bearing WT and ST2/ mice at day 13 after tumor inoculation were determined by flow cytometry.
Representative dot plots defining CD27high/CD27low and CD11b1/CD3CD19NKp461 cells are shown. (B) The percentages and absolute numbers
of CD691 and KLRG1 NK cells in the spleens and local lymph nodes of healthy and tumor-bearing WT and ST2/ mice at day 13 after tumor
inoculation were determined by flow cytometry. Representative flow cytometry dot plots show percentages of CD691 and KLRG
CD3CD19NKp461 cells in spleens and local lymph nodes from ST2/ and WT mice. Data are mean1SD from four mice per group. Statistical
significance was determined by Student’s t-test (po0.05; po0.01).
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In summing up, we provide the first evidence that deletion of
ST2 signaling may enhance antitumor immune response in a
murine model of metastatic breast carcinoma. The increased anti-
tumor immunity of ST2-deficient mice could be based on two
independent mechanisms, both directed against tumor cells:
Th1/Th17 polarization of adaptive immune response with increased
proinflammatory cytokines and cytotoxic activity of NK cells. In
addition, these two mechanisms could interact and complement
each other. Thus, it appears that IL-33/ST2 signaling facilitates
primary tumor progression and metastatic dissemination probably
by affecting the cytotoxic activity and cellular makeup of local
lymph nodes and spleen, indicating an important regulatory role of
the IL-33/ST2 pathway in NK physiology and antitumor immunity.
Materials and methods
Mice
Female BALB/c (WT) and ST2 knockout (ST2/) mice on
BALB/c background (generated as described previously by
Townsend et al. [28]), 10 to 11 wk old, were used in
experiments. ST2/ and WT mice were housed under standard
laboratory conditions. The WT and the ST2/ mice were kept in
two locations (Kragujevac, Serbia and Rijeka, Croatia) and they
were intercrossed and typed. The experiments were approved by
the Animal Ethics Board of the Faculty of Medicine, University of
Kragujevac, Serbia.
4T1 tumor cell line
The weakly immunogenic mouse breast tumor cell line 4T1 that is
syngeneic to the BALB/c background was purchased from the
American Type Culture Collection (ATCC, USA). 4T1 cells were
maintained in Dulbecco’s-Modified Eagles Medium supplemented
with 10% fetal bovine serum, 2mmol/L L-glutamine, 1mmol/L
penicillin–streptomycin, 1mmol/L mixed nonessential amino
acids (Sigma, USA) (complete growth medium). Subconfluent
monolayers, in log growth phase, were harvested by brief
treatment with 0.25% trypsin and 0.02% EDTA in phosphate-
buffered saline (PBS, PAA Laboratories GmbH) and washed three
times in serum-free PBS before use in all in vitro and in vivo
experiments. The number of viable tumor cells was determined
by trypan blue exclusion and only cell suspensions with Z95%
viable cells were used.
Estimation of in vivo tumor growth and progression
in 4T1 metastatic breast cancer model
Mice were injected with 50 mL of single-cell suspension contain-
ing 5 104 4T1 mammary carcinoma cells orthotopically into the
Figure 7. Tumor growth after in vivo depletion of CD81 and NK cells. (A) Mice were injected with 5 104 4T1 tumor cells and primary tumor growth
was evaluated by measuring tumor diameters on day 17 after tumor inoculation in CD81 cell-depleted WT and ST2/ mice. Representative flow
cytometry dot plot shows the percentages of CD81 cells after in vivo administration of anti-CD8 mAb (YTS 169.4, left panel). Data are mean1SD
from four mice per group. Statistical significance was determined by Student’s t-test (po0.05). (B) Mice were injected with 5 104 4T1 tumor cells
and primary tumor growth was evaluated by measuring tumor diameters on day 17 after tumor inoculation in NK-depleted WT and ST2/ mice.
Representative flow cytometry dot plot shows the percentages of NK cells after in vivo administration of antiasialo GM1 mAb (left panel). Data are
mean1SD from four mice per group.
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fourth mammary fat pad of mice as described previously [43].
The size of primary tumors was assessed morphometrically
from day 7 using electronic calipers in two dimensions.
Tumor volumes were calculated according to the formula: tumor
volume (mm3)5 LW2/2, where L represents the major axis
(largest cross-sectional diameter) of the tumor, whereas W
represents minor axis [44], and the data were presented as
mean1standard error (mean1SEM). Thirty-six days after tumor
cell injection, mice were sacrificed and the primary tumors were
surgically removed. Blood was taken from the abdominal aorta.
Lung, liver, and brain tissue were collected for the assessment of
the presence of metastasis. Specimens of lungs, liver, and brain
tissue were routinely embedded in paraffin, stained with
hematoxylin and eosin (H&E) and reviewed to confirm the
presence of metastatic colonies. Although tumor cells appeared
heterogeneous in size, they were easily differentiated as
predominately larger cells with an elevated nuclear to cytoplasm
ratio. In total, 4mm hematoxylin and eosin-stained sections from
at least three different levels were examined. The number and
size of metastatic colonies was examined with light microscope
by an independent observer.
Measurement of cytokines
Serum levels of IL-17, IFN-g, IL-4, and TNF-a were measured
using highly sensitive enzyme-linked immunosorbent assay
(hs-ELISA) kits (R&D Systems, Minneapolis, MN, USA), specific
for the mouse cytokines, according to the manufacturer’s
instructions.
Cellular analysis of local lymph nodes and spleens
Thirteen days after 4T1 tumor cells injection, mice were
sacrificed and single-cell suspensions from spleen and the local
lymph node (the nearest lymph node that drains the primary
tumor) were obtained by mechanical dispersion through cell
strainers (BD Pharmingen, USA) in complete growth medium.
Additionally, erythrocytes from spleen were removed using lysing
solution (BD Pharmingen). After three washes, cells were
resuspended in complete growth medium.
Flow cytometry
Single-cell suspensions of local lymph nodes and spleens were
incubated with mAbs specific for mouse CD3, CD4, CD8, CD19, F4/
80, NKp46, CD107a, NKG2D, CD27, CD11b, CD69, and KLRG1 or
isotype-matched controls (BD Pharmingen/eBioscience) and
analyzed by FACSAria flow cytometer (BD Biosciences). Dead cells
were excluded by gating out propidium iodide-positive cells. The
gate used for FACS analysis is the mononuclear cells region in FSC/
SSC plot. Data were analyzed using CELLQUEST software and DiVa
(BD).
Intracellular cytokine staining
Single-cell suspensions of spleens were stimulated with Phorbol
12-myristate 13-acetate (50 ng/mL) (Sigma) and Ionomycin
(Sigma) (500 ng/mL) with GolgiStop (BD Pharmingen), and
incubated 4 h at 371C, 5% CO2. Cells were stained with anti-
NKp46 mAb or isotype-matched control. Subsequently, cells were
fixed, permeabilized, and intracellular staining was done using
anti-IFN-g and anti-IL-10 mAb (BD Pharmingen) and analyzed by
flow cytometry.
NK cell separation
NK cells were isolated from spleen and local lymph node by
magnetic cell sorting. Target cells were labeled using Flow-
CompTM Mouse CD49b Ab (Invitrogen, USA), captured by the
Dynabeads (Invitrogen), and positively selected using magnet
(Invitrogen). In the last step, the beads were removed from the
cells, using FlowCompTM Release buffer (Invitrogen).
CD81 T-cell separation
CD81 T cells were isolated from spleen and the local lymph
node by depleting non-CD81 T cells (CD41 T cells, B cells,
monocytes/macrophages, NK cells, DCs, erythrocytes, and
granulocytes). Mixture of monoclonal Abs against non-CD81
T cells (Invitrogen) was added to cell suspensions, following by
Mouse Depletion Dynabeads (Invitrogen) and bead-bound
cells were separated by a magnet (Invitrogen). Remaining cells
were highly enriched mouse CD81 T cells (purity, 490%).
Cytotoxicity assays
Cytotoxic activity of lymph node cells, splenocytes, enriched NK
cells, enriched CD81 T cells, and adherent cells was measured
using the 4 h MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide, Sigma) assay at various target–effector
(T:E) ratios as described previously [41]. 4T1 mouse breast
tumor cells were used as targets. The percentage of cytotoxity
was calculated as: cytotoxity (%)5 (1(experimental group
(OD)/control group (OD)))100. Data were expressed as the
mean of triplicate wells1SEM. Cytotoxic activity was also
presented by lytic units, LU20/10
7 cells, calculated from means
of triplicate percentages of killing obtained in four different T:E
ratios [45].
In vivo depletion of NK and CD81 cells during tumor
challenge
For in vivo depletion of NK and CD81 cells, mice were treated
i.p. with 100mg of anti-CD8 mAb (YTS 169.4) or with 20mL of
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anti-asialo GM1 (Waco. Bioproducts), 1 day prior to and 5 days
after tumor inoculation. The efficacy of depletion of cells was
assessed 24 h after Ab administration by flow cytometry of
splenocytes stained with APC-labeled anti-CD8 and APC-labeled
NKp46 Abs (eBioscience). The level of depletion was 495% for
both cell subsets.
Statistical analysis
The data were analyzed using statistical package SPSS, version
13. The two-tailed Student’s t-test or nonparametric Mann–Whit-
ney Rank Sum test were used. The normality of distribution was
tested by Kolmogorov–Smirnov test. The results were considered
significantly different when po0.05 and highly significantly
different when po0.01.
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